| Document |
Document Title |
|
WO/2016/109679A1 |
A method of treating symptoms of schizophrenia includes enterically administering to a subject a pharmacological agent that inhibits presynaptic glutamate release, modulates postsynaptic glutamate response, or both. Embodiments herein re...
|
|
WO/2016/103262A2 |
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...
|
|
WO/2016/089951A1 |
The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/composi...
|
|
WO/2016/089208A2 |
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...
|
|
WO/2016/086885A1 |
Disclosed are a deuterated organic compound, a mixture and composition containing said compound, and an organic electronic device; the deuterated organic compound has the structural formula (I): an aromatic or heteroaromatic structural u...
|
|
WO/2016/088864A1 |
The present invention addresses the problem of providing a compound suitable as a pharmaceutical composition, especially as a therapeutic agent for nocturia. It was hoped that inhibiting placental leucine aminopeptidase (P-LAP), which is...
|
|
WO/2016/083914A1 |
Provided is a 4-oxoquinoline compounds of the formula (I) (I) wherein A is selected from diradicals of the formulae (A.1), (A.2), (A.3), (A.4), (A.5) and (A.6), (A.1) (A.2) (A.3) (A.4) (A.5) (A.6) wherein R 1, R 2a, R 2b, R 3, R 3a, if p...
|
|
WO/2016/083915A1 |
The present invention relates to a 4-hydroxquinoline compounds of the formula (I) wherein A is selected from diradicals of the formulae (A.1), (A.2), (A.3), (A.4), (A.5), and (A.6) wherein R 1, R 2a, R 2b, R 3, if present R 4a, R 4b, R 5...
|
|
WO/2016/076573A2 |
The present invention relates to a method for producing high-purity blonanserin at a high yield under mild reaction conditions, and an intermediate used therefor.
|
|
WO/2016/066142A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
|
|
WO/2016/066134A1 |
The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown by formula I, a pharmaceutical composition containing the co...
|
|
WO/2016/068633A2 |
The present invention relates to a nitrogen-containing polycyclic compound and an organic light emitting element comprising the same.
|
|
WO/2016/054406A1 |
The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate ceil growth, differentiation, proliferation, an...
|
|
WO/2016/054286A1 |
A method of resolving a racemic mixture of (±) Huperzine A to (-)-Huperzine A includes: separating the (-)-Huperzine A from the racemic mixture of (±) Huperzine A by chiral high performance liquid chromatography (HPLC), the chiral HPLC...
|
|
WO/2016/043941A1 |
Novel photoacid generator compounds are provided. Photoresist compositions that include the novel photoacid generator compounds are also provided. The invention further provides methods of making and using the photoacid generator compoun...
|
|
WO/2016/043558A1 |
The present invention relates to a compound, wherein the compound comprises at least one structural element A and at least one structural element B, wherein - structural element A is capable of releasing an acid upon exposure to electrom...
|
|
WO/2016/041511A1 |
The present invention relates to benzoxazole derivatives having Formula (I). The compounds of the present invention are found to possess the ability to decrease PD-L1 level, suggesting that the compounds of the invention can be used in c...
|
|
WO/2016/027687A1 |
An organic EL element according to the present invention sequentially comprises a positive electrode, a hole transport layer, a light emitting layer, an electron transport layer and a negative electrode in this order, and is characterize...
|
|
WO/2016/028225A1 |
The present invention relates to platinum compounds of Formula (I) or (II) as defined herein as well as their use for the treatment of cancer, methods for treating cancer in a subject using said compounds, and methods for triggering apop...
|
|
WO/2016/016498A1 |
Method for producing PDI derivatives. The invention relates to a method for producing perylene diimide derivatives of formula I where R1, R2 and R3 have the designation indicated in the description. Said compounds are used to produce dye...
|
|
WO/2016/019125A1 |
Described herein are coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3- ( 1-methyl- 1H- 1,2,4-triazol-5-yl)-4-oxo-l,2,3,4-tetrahydroquinoline-5-carb
oxylate optionally as a solvate and additionally optionally as a hydrate, i...
|
|
WO/2016/014797A1 |
The invention relates to novel compounds and pharmaceutical preparations thereof, as well as methods of making and using these compounds. The invention further relates to methods of treating or preventing disease using the novel compound...
|
|
WO/2016/007534A1 |
The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the...
|
|
WO/2016/003202A2 |
The purpose of the present invention is to provide a compound that can improve the lifespan, low drive voltage and high luminous efficiency of an element, an organic electronic element using same, and an electronic device comprising same.
|
|
WO/2016/004228A1 |
The present invention generally relates to fluorescent marking compositions and their use to determine whether a surface has been cleaned. More particularly, the marking compositions comprise fluorescent polymers.
|
|
WO/2015/198349A1 |
The present invention provides a one pot, simple, cost effective and industrially feasible catalytic synthesis of quinolines or substituted quinolines from anilines with yield >80% yield. The present invention also discloses a process fo...
|
|
WO/2015/191735A1 |
Water-soluble triazabutadiene molecules and methods for producing and using such compounds. The triazabutadiene molecules may be more labile at pH levels below physiological pH, such as pH 7, pH 6, pH 5, etc. The triazabutadiene molecule...
|
|
WO/2015/191837A1 |
The present disclosure provides oxidized berbine derivatives, processes for their preparation, and methods of using the oxidized berbine derivatives.
|
|
WO/2015/187932A1 |
Provided are methods and compositions useful in reducing drug-induced sedation in subjects, wherein the compositions comprise an opioid and a dopaminergic agent. The dopaminergic agent is selected from L-DOPA, a dopamine agonist, a MAO i...
|
|
WO/2015/179999A1 |
Disclosed are a ratio-type fluorescent probe substrate of cytochrome oxidase CYP1A and a use thereof, which belong to the technical field of biomedicine. The specific probe substrate has a structure of a hydroxy-naphthalimide-alkanoic ac...
|
|
WO/2015/178585A1 |
Disclosed is a compound represented by Chemical Formula 1. Also disclosed is an electro-organic device including a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode, wherein th...
|
|
WO/2015/179448A1 |
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein D, V, and R3 a...
|
|
WO/2015/176640A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2015/176267A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR 40) and may be useful in the treatment, prevention and suppression of diseases mediated ...
|
|
WO/2015/172134A1 |
The present invention provides quenchers of excited state energy, probes and other conjugates comprising these quenchers, and methods of their use.
|
|
WO/2015/160688A1 |
The invention provides novel azaborine compounds, methods for their syntheses and functionalization, and various applications thereof. For example, novel azaborine-containing biarylcarboxylic acids and biarylcarboxamides are disclosed he...
|
|
WO/2015/161016A1 |
The present invention is directed to bicyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmace...
|
|
WO/2015/153683A1 |
This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses me...
|
|
WO/2015/154023A1 |
The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inf...
|
|
WO/2015/143654A1 |
The present invention is directed to six membered heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, can...
|
|
WO/2015/147247A1 |
A compound represented by formula (I) or formula (VI), which has antiviral activity, especially HIV replication inhibitory activity; and a pharmaceutical product which contains this compound. (In the formulae, ring A represents a substit...
|
|
WO/2015/138377A1 |
Methods of killing or inhibiting the growth cancer cells and tumors and of treating cancer by administering compounds that stimulate the activity of RAD51. Cells overexpressing RAD51 or with other imbalances in homologous recombination m...
|
|
WO/2015/125085A1 |
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are G...
|
|
WO/2015/119848A1 |
The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "Ra" is independently H or -F, in a water-soluble polymer matrix which f...
|
|
WO/2015/120059A1 |
This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.
|
|
WO/2015/115116A1 |
Provided is an organic light emitting element which exhibits stable performance in the atmosphere. This organic light emitting element comprises a positive electrode, a negative electrode and a first organic compound layer that is arrang...
|
|
WO/2015/112707A1 |
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. (Formula (I))
|
|
WO/2015/109056A1 |
The present invention discloses a probe useful for the selective detection of metallo-beta-lactamases, in particular carbapenemases, thereby distinguishing those species of bacteria that are carbapenem-resistant from bacterial strains th...
|
|
WO/2015/104343A1 |
It relates to spirocyclic compounds of formula (I), or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wher...
|
|
WO/2015/099863A1 |
The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R', R", R"' R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is als...
|
